BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genelex Corporation Release: FDA Committee Supports Simple DNA Tests When Patients Are Prescribed Coumadin (Warfarin)


11/21/2006 10:14:34 AM

SEATTLE, Nov. 20 /PRNewswire/ -- A blue-ribbon advisory committee to the FDA has recommended genotyping patients at the beginning of Coumadin (generic name warfarin) therapy to allow patients to be more quickly stabilized at safe and effective dosage levels. The FDA committee points out that genotyping by DNA testing can help to reduce potentially fatal and serious adverse reactions to the drug.

Historically, achieving the correct dose of warfarin was a matter of "trial and error" often requiring many months; leaving patients vulnerable to deadly bleeding reactions or recurrent stroke, thromboembolism, or other adverse clotting events.

According to the FDA, hemorrhage during warfarin therapy is a one of the country's leading causes of death due to a prescribed drug and adverse issues related to warfarin therapy are the cause of one in ten hospital admissions. The new tests, offered by Genelex Corporation, allow physicians to more accurately determine the correct warfarin dose. "This is a perfect example of the new movement towards personalized medicine, based on the individuals DNA, rather than prescription by trial and error. The age of "one dose fits all" is ending," Genelex CEO Howard Coleman stated.

To help educate physicians and patients about the test, Genelex has launched a new, free, Internet presentation that details how DNA tests can reduce potentially fatal side effects connected to warfarin. The site also includes computerized information to help patients AND physicians interpret test results.

The Genelex test is simple, requiring no more effort than vigorously rubbing the inside of the cheek with a cotton-tipped swab and sending it to Genelex's laboratory for testing. No prescription is needed, and insurance often pays for the test.

Many experts agree that the use of DNA testing will dramatically improve the safety and efficacy of warfarin.

For further information, consumers can view the Coumadin (warfarin) Web Seminar free of charge by going to www.Genelex.com. Information about test purchase and interpretation of test results is also available at Genelex.com. Further questions on this release should be directed to Genelex CEO Howard Coleman, 800 523-3080.

Genelex Corporation

CONTACT: Howard Coleman of Genelex Corporation, +1-800-523-3080



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES